Inhibitor Therapeutics, Inc.
INTI · OTCMCIK 1042418fmd_1YACR9067Y28Q8X69WCQJEDT5QManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2012 to Jun 30, 2026, 56 periods
Latest annual · FY2021
Millions- Total revenues
- 0
- Operating income
- (3)
- Net income
- (3)
Latest quarter · Q2 FY2026
Millions- Operating income
- (1)
- Net income
- (1)
Key stats
Open AnalysisCompound annual growth
- Net income, 5 yearsFY2020 to FY2025
- n/m
Inhibitor Therapeutics, Inc. (INTI) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Operating income | -$3.4 million | -$3.7 million | 10-K 2026-03-26 · proof | |
| Net income | -$3.3 million | -$3.3 million | 10-K 2026-03-26 · proof | |
| Cash from operating activities | -$3.2 million | -$3.2 million | 10-K 2026-03-26 · proof | |
| Total assets | $2.5 million | $5.7 million | -55.9% | 10-K 2026-03-26 · proof |
| Total liabilities | $3.8 million | $3.7 million | +2.5% | 10-K 2026-03-26 · proof |
| Cash and cash equivalents | $2.4 million | $5.6 million | -57.6% | 10-K 2026-03-26 · proof |
| Total debt | $61,613 | 10-K 2026-03-26 · proof |
- What was Inhibitor Therapeutics, Inc. (INTI)'s operating income in fiscal 2025?
- Inhibitor Therapeutics, Inc. (INTI) reported operating income of -$3.4 million for fiscal 2025 (the year ended Dec 31, 2025), against -$3.7 million the year before. Source: the 10-K filed with the SEC on Mar 26, 2026. SEC
- What was Inhibitor Therapeutics, Inc. (INTI)'s net income in fiscal 2025?
- Inhibitor Therapeutics, Inc. (INTI) reported net income of -$3.3 million for fiscal 2025 (the year ended Dec 31, 2025), against -$3.3 million the year before. Source: the 10-K filed with the SEC on Mar 26, 2026. SEC
- What was Inhibitor Therapeutics, Inc. (INTI)'s cash from operating activities in fiscal 2025?
- Inhibitor Therapeutics, Inc. (INTI) reported cash from operating activities of -$3.2 million for fiscal 2025 (the year ended Dec 31, 2025), against -$3.2 million the year before. Source: the 10-K filed with the SEC on Mar 26, 2026. SEC
- What are Inhibitor Therapeutics, Inc. (INTI)'s total assets?
- As of Dec 31, 2025, Inhibitor Therapeutics, Inc. (INTI) reported total assets of $2.5 million, against $5.7 million a year earlier (-55.9%). Source: the 10-K filed with the SEC on Mar 26, 2026. SEC
- What are Inhibitor Therapeutics, Inc. (INTI)'s total liabilities?
- As of Dec 31, 2025, Inhibitor Therapeutics, Inc. (INTI) reported total liabilities of $3.8 million, against $3.7 million a year earlier (+2.5%). Source: the 10-K filed with the SEC on Mar 26, 2026. SEC
- What are Inhibitor Therapeutics, Inc. (INTI)'s cash and cash equivalents?
- As of Dec 31, 2025, Inhibitor Therapeutics, Inc. (INTI) reported cash and cash equivalents of $2.4 million, against $5.6 million a year earlier (-57.6%). Source: the 10-K filed with the SEC on Mar 26, 2026. SEC
- What is Inhibitor Therapeutics, Inc. (INTI)'s total debt?
- As of Dec 31, 2025, Inhibitor Therapeutics, Inc. (INTI) reported total debt of $61,613. Source: the 10-K filed with the SEC on Mar 26, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:INTI&period_type=annual&limit=5"Information only, not investment advice.